PubMed Health⌕ Search

Biomedical subjects

G Mantovani

Publications and source records attributed to G Mantovani.

At least 19 recordsLinked to original sources
PubMed1992

Measurement of tryptase in endoscopic gastroduodenal biopsies: distribution and relationship with ulcer disease.

Tryptase, a serine endoprotease, was determined in mucosal biopsies from fundus, corpus, antrum and corpus-fundus of the stomach and from the duodenum in 15 controls, 66 patients with duodenal ulcer, 22 with gastric ulcer and 9 with duodenitis. Intra- and inter-assay coefficients of variation ranged from 3.3% to 8.0% and from 3.5% to 8.6%, respectively. In controls, the highest values for tryptase were found in the fundus and progressively decreased in the corpus, antrum and duodenum. Analysis of variance of data from repeated measurements, performed in six subjects having multiple determinations, achieved statistical significance (F = 16.85, P less than 0.001). Data from the corpus-fundus area documented a significant difference among patient groups (F = 2.70, P less than 0.05). Patients with an active gastric ulcer had higher mean values when compared to controls and to patients with healed gastric ulcer. A similar trend was found in patients with active duodenal ulcer. Furthermore, corpus-fundus tryptase evaluated longitudinally in three patients with an active ulcer (point A) and after healing (point B), showed significant decrease from point A to point B. By contrast it remained elevated or showed only minor decrease in two patients with a persistent active ulcer.

Adult↗
PubMed1992

[Controlled trial of thymostimulin treatment of patients with primary carcinoma of the larynx resected surgically. Immunological and clinical evaluation and therapeutic prospects].

The study aim was that of evaluate the effect of thymostimulin (Tp-1, Serono), either in vitro or in vivo, in patients with primary laryngeal carcinoma, treated only with surgery without any other complementary therapy. Nineteen patients have been studied: nine (mean age 62.5 years, range 48-70) have been treated with Tp-1 and ten patients (mean age 63.4 years, range 56-75) served as "controls". Tp-1 has been administered as follows: 60 mg/m2/daily i.m. days 1-15; 60 mg/m2 twice weekly i.m. days 16-30; 60 mg/m2 once weekly i.m. days 31-60. The treatment was stopped days 61-90. The same cycle was repeated until day 180. The treatment was stopped days 181-365. The following parameters have been assessed: clinical (at the protocol entry and after one year): Performance Status (PF, Karnofsky), local status, presence of relapses, incidence of chronic infections of the upper respiratory tract; immunological in vitro: 1) response to polyclonal mitogens, PHA, Con A and PWM, response to human recombinant Interleukin 2 (rIL 2) of PHA-prestimulated and non prestimulated peripheral blood lymphocytes. The immunological parameters also have been assessed at the protocol entry and after one year. Our results have shown that, in the group of patients treated with Tp-1, 5/9 patients (55.56%) exhibited a significant increase of the PHA response at the end of treatment as compared to pretreatment values, 3/9 (33.34%) showed a decrease and 1/9 (11.10%) an almost unchanged response. In the group of controls, 5/10 (50%) have shown a significant decrease of the response after one year, 3/10 (30%) an increase, 1/10 (10%) were unchanged and 1/10 (10%) exhibited a non univocal response.(ABSTRACT TRUNCATED AT 250 WORDS)

Adjuvants, Immunologic↗
PubMed1978

Response to neoplastic antigens in human oncology: assessment and results of LIF (leucocyte inhibitory factor) test in breast cancer patients.

The leucocyte inhibition factor (LIF) test, revealing the inhibition of leucocyte migration from capillary tubes, was studied with leucocytes from 47 patients with breast cancer, from 14 patients with benign breast tumors, and from 56 normal subjects. As antigens we used formalin-fixed tumor cells. The LIF assay was positive in 38/47 (80.8%) breast cancer patients, in 10/14 (71.4%) benign breast tumor patients, and in 13/56 (23.2%) normal subjects. The negative LIF assays were higher with leucocytes from patients with metastases than with those from patients with no metastases. We found no correlation between the LIF-test response and the histopathologic pattern of the tumors, type of treatment (almost always surgical), and remission or relapse state of our patients at the time of testing.

Adult↗
PubMed1978

[Action of various mitogens (phytohemagglutinin, cocanavalin A, pokeweed mitogen) on a purified human B- and T-lymphocyte population mediating spontaneous rosette formation].

The activity of various most widely used "polyclonal" mitogens, such as PHA, Con A and PWM on human peripheral blood lymphocyte subpopulations, after separation into the two main functional classes (B and T), was investigated. For separating the lymphocyte subclasses, the E-rosette formation technique has been followed, using the gradient centrifuged pellet and supernatant respectively. For the mitogens' activity evaluation, micro-culture system has been performed and 3H thymidine uptake has been assessed. The PHA has been shown to be much more active on the T lymphocyte subclass, though the mitogen cannot be kept very selective. Very much higher activity on the T subclass shows the Con A, which could be considered selective, if we hypothesize an at least partial receptor competition at lymphocyte membrane level between the mitogen and sheep erythrocytes. The PWM has been found very little active and not specific for either lymphocyte subclass.

Adult↗
PubMed1978

[Spontaneous blast formation of spontaneous rosette-forming human lymphocytes with sheep and mouse erythrocytes: morphological demonstration].

A high uptake rate of 3HTdR by human cultured rosette-forming lymphocytes with sheep or mouse erythrocytes without stimulation has been already found occasionally in a discrete percentage of experiments by the Authors. In this paper morphologic evidence is shown that in those cultures "blastic" or "blast-like" cells are present, probable expression of spontaneous lymphocyte activation by "rosetting" phenomenon.

Animals↗
PubMed1976

[Comparison between anti-lymphocyte antibodies in systemic lupus erythematosus and in Hodgkin's disease].

Anti-lymphocyte antibodies of cold-reactive IgM-type in Systemic Lupus Erythematosus (SLE) and IgG-type in Hodgkin's disease (HD) by means of immunofluorescent technique have been demonstrated. The contemporaneous attachment of SLE and HD sera on selected peripheral lymphocytes demonstrate that the target cell is T-lymphocyte and that the two kinds of antibodies coat the same cell. Co-capping experiments have shown that the phenomenon has the same behaviour as regard to SLE and HD antibody, indicating that the antigen is the same. Hypothesis about the meaning of these antibodyies have been made.

Antibody Formation↗
PubMed1976

[Presence of alpha-2-macroglobulin on the membrane of peripheral human blood lymphocytes : a new lymphocyte maker].

The presence of alpha-2-macroglobulin (alpha-2-M) on the surface of peripheral blood lymphocytes from normal human subjects and from patients with chronic lymphatic leukaemia (CLL) and with ataxia-teleangectasia was studied by indirect immunofluorescence technique. Same experiments were done on purified subpopulations of normal blood peripheral lymphocytes (B and T). The percentage of alpha-2-M bearing lymphocytes is 17 +/- 6% as regard to normal subjects (Ig-bearing cells are 14%): in CLL the percentage of alpha-2-M bearing cells generally is significantly lower than that of Ig-bearing cells (IgM-IgD). On selected subpopulations, 90% of alpha-2-M bearing cells are present among non T-cells and only 5% among T-cells (probably due to not absolute purification). Blocking experiments using anti-Ig sera did not affect significantly the percentage of alpha-2-M bearing cells and using anti-alpha-2-M sera did not affect that of Ig-bearing cells. The percentage of E-rosette forming cells is not affected by pretreatment of peripheral lymphocytes with anti-Ig and/or anti-alpha-2-M sera. Hypothesis is set forth that alpha-2-M bearing cells could be a lymphocytes subpopulation made by a subgroup of B-cells and by K-cells, taking part in that immunoregulatory system in which collaborate many serum alpha-globulins and T-suppresor cells.

Antibody Formation↗
PubMed1976

Anti-lymphocyte antibodies in systemic lupus erythematosus and in Hodgkin's disease: a comparison by immunofluorescence.

Anti-lymphocyte antibodies of IgM type (cold reactive) in systemic lupus erythematosus and of IgG type (not cold reactive) in Hodgkin's disease have been demonstrated by immunofluorescence to attach the same target cell (T-lymphocyte.) The same behaviour of both kinds of antibodies in "co-capping" experiments confirm that the antigen on the cell surface is the same. Hypothesis about the meaning of this phenomenon are made.

Antilymphocyte Serum↗